Diabetes Clinical Trials in New York

Showing 421-440 of 582 trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

NCT00212329

Type 1 diabetes is a condition that is caused in part by an abnormality of the immune system which occurs when T cells, which are part of the immune system, damage the insulin secreting cells (islet cells) in the pancreas. Although it is known that T cells are important mediators of the disease, progress in the development of reliable T cell assays has been modest. The purpose of this study is to learn which T cell assays are most reliable and reproducible so that the investigators can improve their understanding about how type 1 diabetes occurs.

Type 1 Diabetes Mellitus

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)100 participantsStarted Sep 2005

Los Angeles, California, United States • San Francisco, California, United States • Stanford, California, United States +11 more locations

COMPLETEDNA< 1 mile

Glucose Meter Study

NCT00782496

The purpose of this study is to evaluate if the meal marker and reminder feature of the Contour meter along with education maintains or increases frequency of testing blood sugar after meals and enables behavioral changes that may lead to improvement in glycemic control.

Diabetes Mellitus

Ascensia Diabetes Care211 participantsStarted Nov 2008

Atlanta, Georgia, United States • Minneapolis, Minnesota, United States • New York, New York, United States +1 more locations

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

Glucose Meter Study

Diabetes Trials in Other Cities

Mobile Phone-based Intervention for Promoting Healthy Habits and Weight Loss

Mechanisms of Diabetes Control After Weight Loss Surgery, Sub-study #1

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Study of an Investigational Glucose Meter System

Performance of an Investigational Blood Glucose Monitoring System

Evaluation of the A1CNow+ Test Kit

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

Other Conditions in New York